Stockscreener 앱 받기
8.62
0.92%
-0.07
Iteos Therapeutics Inc 주식(ITOS)의 최신 뉴스
(ITOS) Trading Advice - news.stocktradersdaily.com
Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN
Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha
Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada
ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts
ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus
Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks
ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com
HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus
iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus
iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus
Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks
iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India
GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues
ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - biocentury.com
iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha
iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia
GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria
iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus
GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash PileITeos Therapeutics (NASDAQ:ITOS) - Benzinga
iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus
iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive
ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq
ITeos, GSK discontinue lung cancer therapy development - KFGO
Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com
GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus
GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com
iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa
iTeos stock rises despite clinical trial setback - Investing.com Australia
iTeos (ITOS) Takes Strategic Steps After Disappointing Study Res - GuruFocus
GSK Ends Small-Molecule Drug Belrestotug Development Program - marketscreener.com
GSK, iTeos End Development of Experimental Lung Cancer Drug - Bloomberg.com
17.27%
자본화:
|
볼륨(24시간):